PD-L1 blockade has shown efficacy in seven cases of refractory NKTCL, and given that STAT3 drives PD-L1 expression, there may be a benefit in combining these therapeutic strategies [70]. The gene discussed is CD274; the disease is extranodal nasal NK/T cell lymphoma.